GleamWall
中文EN

INBP INTEGRATED BIOPHARMA INC

Pharmaceutical Preparations · OTC · SEC CIK 1016504 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-23.1%
TTM net income YoY-644.0%
TTM EPS YoY-650.0%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin-0.8%
Operating margin-9.3%
Net margin-8.9%
FCF margin-3.8%
EBITDA margin-8.6%

Returns

ROE-19.5%
ROA-14.8%
ROIC (approx.)-20.4%
Asset turnover1.66x

Leverage & solvency

Liabilities / assets29.2%
Debt / equity0.00x
Current ratio2.93x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$43.87M$54.35M
Cost of revenue$43.07M$48.79M
Gross profit$800,000$5.56M
SG&A expense$3.50M$3.54M
Operating income-$2.71M$2.02M
Interest expense$12,000$46,000
Pretax income-$2.56M$2.06M
Income tax$279,000$1.25M
Net income-$2.84M$808,000
EBITDA-$2.41M$2.34M
EPS (basic)-0.090.03
EPS (diluted)-0.090.03
Weighted avg. shares (diluted)31.06M31.17M
Balance sheet
Cash & equivalents$4.47M$3.62M
Receivables$3.33M$5.43M
Inventory$9.14M$9.36M
Current assets$17.38M$18.76M
PP&E, net$1.75M$1.72M
Total assets$25.34M$24.90M
Current liabilities$5.80M$4.25M
Total liabilities$7.67M$4.58M
Shareholders' equity$17.67M$20.32M
Shares outstanding31.06M31.06M
Cash flow statement
Operating cash flow$1.24M$2.06M
Capital expenditure$346,000$191,000
Free cash flow$895,000$1.87M
Investing cash flow-$340,000-$205,000
Financing cash flow-$45,000$78,000
Depreciation & amortization$293,000$318,000
Stock-based compensation$192,000$185,000

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.